Kirchhoff, H.; Ricke-Hoch, M.; Wohlan, K.; Pietzsch, S.; Karsli, Ü.; Erschow, S.; Zweigerdt, R.; Ganser, A.; Eder, M.; Scherr, M.;
et al. Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. Cancers 2022, 14, 983.
https://doi.org/10.3390/cancers14040983
AMA Style
Kirchhoff H, Ricke-Hoch M, Wohlan K, Pietzsch S, Karsli Ü, Erschow S, Zweigerdt R, Ganser A, Eder M, Scherr M,
et al. Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. Cancers. 2022; 14(4):983.
https://doi.org/10.3390/cancers14040983
Chicago/Turabian Style
Kirchhoff, Hanna, Melanie Ricke-Hoch, Katharina Wohlan, Stefan Pietzsch, Ümran Karsli, Sergej Erschow, Robert Zweigerdt, Arnold Ganser, Matthias Eder, Michaela Scherr,
and et al. 2022. "Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart" Cancers 14, no. 4: 983.
https://doi.org/10.3390/cancers14040983
APA Style
Kirchhoff, H., Ricke-Hoch, M., Wohlan, K., Pietzsch, S., Karsli, Ü., Erschow, S., Zweigerdt, R., Ganser, A., Eder, M., Scherr, M., & Hilfiker-Kleiner, D.
(2022). Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart. Cancers, 14(4), 983.
https://doi.org/10.3390/cancers14040983